treatments is recommended.
PHOTOTHERAPY IN DERMATOLOGY
Phototherapy modalities utilize specific wavelengths of the electromagnetic spectrum to disrupt the dysfunctional and pathologic tissue that has developed in some patients with skin disease. Various phototherapy modalities possess anti-inflammatory effects [1] . The longer the wavelength of phototherapy, the deeper in the dermis it penetrates [2] . Current phototherapeutic modalities being used for dermatoses include broadband ultraviolet B
(UVB 290-320 nm), narrowband UVB (311-313 nm), excimer laser (308 nm), ultraviolet A (UVA 320-400 nm), ultraviolet A1 (UVA1 340-400 nm), psoralen and UVA (PUVA), and extracorporeal photochemotherapy.
MECHANISM BEHIND PHOTOTHERAPEUTIC MODALITIES USED IN SCLERODERMA
A common theory behind the mechanism of phototherapy in scleroderma is that light is converted to chemical energy resulting in the increase of reactive oxygen species or singlet oxygen production, which can modulate the expression of cytokines [3, 4] . Ultraviolet radiation includes UVA and UVB therapy, with UVA1 studied the most. UVA1 can have an output categorized as low (10-30 J/cm UVA1 radiation increases collagenase [also known as the matrix metalloproteinase-1 (MMP-1)] gene, mRNA, and protein expression by fibroblasts [5] [6] [7] [8] [9] . In mice models, UVA1 radiation reduces fibroblast proliferation in a dose-dependent fashion [10, 11] . Additionally, UVA1 radiation administered three times a week showed decreased hydroxyproline and collagen levels in a dose-dependent fashion [11] . The quality of the collagen is altered after UVA1 therapy, as collagen appears less dense and smoother compared to before treatment [12] . Decorin (a proteoglycan component of connective tissue) mRNA levels are lower in lesional scleroderma versus non-lesional skin, and decorin levels are increased after UVA1
phototherapy [13] . Transforming growth factor beta (TGF-b) protein levels (TGF-b is profibrotic) are inversely correlated with decorin levels. On the other hand, another study showed that after UVA1 phototherapy, decorin was decreased in the upper to middle dermis, although decorin slightly increased in the papillary dermis [14] .
In patients, UVA has been shown to reduce collagen I, collagen III, and TGF-b and increase interferon-c [9] . UVB radiation increases alpha melanocyte-stimulating hormone (a-MSH) receptor synthesis in keratinocytes and melanocytes [15] . Human fibroblast dermal cultures treated with a-MSH demonstrated an increase in MMP-1 mRNA, indicating that a-MSH may be one of UVB's mediators of anti-fibrosis [16] .
The source of the mediators that contribute to the reduction in sclerosis comes mostly from the dermis. Subsequently, certain parts of the dermis may be impacted more than others. An image analyzer showed a greater reduction in collagen fibers in the upper and middle dermis and less reduction in the lower dermis [12] . In 18 patients treated with UVA1, the MMP-1 level was higher in the papillary layers and lower in the reticular layers [17] . The anti-fibrotic effects of phototherapy may not come exclusively from the dermis. Samples taken 18 h after the final UVA1 treatment in a set of patients showed an increase in interstitial collagenase in the upper layer of keratinocytes, melanocytes, and endothelial cells [5] .
Evidence supports the regimen of multiple UVA1 therapy sessions a week. The anti-sclerotic effects of a single exposure of UVA1 effects are typically seen to last less than 1 week. In human skin, mRNAs of type I and III procollagen were decreased and MMP-3 was increased after 3 days of a single UVA1 dose [18] . MMP-1 and MMP-3 were upregulated for 3 to 5 days, while procollagen levels were suppressed for at least 7 days [18] . In this small study, anti-fibrotic responses became refractory to multiple UVA1 exposures over the course of 1 week, as repeated exposures weekly showed no reduction in type I procollagen levels [18] .
UVA1
therapy can have an immunomodulatory effect on lesional skin.
UVA1 can reduce inflammation in the dermis [12] . UVA1 causes apoptosis of T-cells [19] . Patients with morphea exposed to UVA1 with a dose of 30 J/cm 2 and a cumulative dose of 900 J/cm 2 were found to have an increase in CD34 ? dendritic cells [20] . Human beta defensin[s] (HBD), interleukin (IL)-6 and IL-8 are downregulated in patients with localized scleroderma treated with UVA1 phototherapy [6] . On the other hand, another study showed that UVA1 induces MMP-1 through a mechanism involving IL-1 and IL-6 [21] . UVA1 radiation may induce oxidative stress, as evidenced by an increase in UVA1-induced heme oxygenase-1 in fibroblasts [7] .
Glutathione was lower in systemic sclerosis 
CD34
? cells [31] . Bath PUVA treatment has effects on collagen cross-links in human skin samples of scleroderma, reducing hydroxylysylpyridinoline and lysylpyridinoline [32] . UVA1 treatment affected collagen fibrils mostly in the upper reticular dermis [33] , whereas PUVA affected collagen fibrils in the upper and middle reticular layers [33] . Additionally, collagen fibrils decreased and new fibrils developed, suggesting UVA1 and PUVA phototherapies' impact on sclerotic lesions occurs via collagen degradation and new collagen synthesis [33] .
Other modalities have also been studied.
Photodynamic therapy (PDT) with 5-aminolevulinic acid (5-ALA) treatment of scleroderma fibroblasts increased MMP-1 and MMP-3, and there was a decrease in collagen type 1 mRNA as early as 6 h after treatment [34] .
Keratinocytes exposed to PDT with 5-ALA had an increase in IL-1a and TNF-a [35] . In fibroblasts that were incubated with keratinocytes pre-exposed to PDT with 5-ALA, there was an increase in MMP-1 and MMP-3;
Karrer et al. [35] subsequently suggested paracrine signaling between the phototherapy exposed keratinocytes and the fibroblasts.
Furthermore, an IL-1 antagonist reversed the induction of MMP-1 and MMP-3 in fibroblasts [35] . Blue light up to 453 nm is toxic to cultured T cells, causing apoptosis, but was nontoxic for other skin cell types [36] .
THE USE OF PHOTOTHERAPY IN DERMATOLOGY
Phototherapy is commonly used for many dermatoses, but there is less usage for scleroderma. Of 653 patients using phototherapy in a Brazilian clinic, 11 were there for scleroderma treatment [37] . In a multi-center response from 155 British pediatric physicians, PUVA was the most popular phototherapy modality (38%), followed by narrowband UVB (23%) and UVA1 (16%) for morphea [38] . These same clinicians
were also asked what would be the best treatment option overall in their opinion for active morphea: 17% responded phototherapy and about 2/3 of these responses were for UVA1, which was only accessible to 27% of respondents [38] . Phototherapy for adult skin disorders is almost exclusively provided by dermatologists [39] . In a survey of physicians treating juvenile localized scleroderma in the UK, 19 of 28 pediatric dermatologists used UV therapy, whereas 0 of 10 pediatric rheumatologists used UV therapy [40] . A self-reported survey of dermatologists and rheumatologists revealed that 20% of dermatologists (n = 40) and 10.6% of pediatric dermatologist (n = 47) used phototherapy [41] . Clinical articles in a non-English language were excluded.
CLINICAL EVIDENCE OF PHOTOTHERAPY'S EFFICACY

Search Method
UVA1
UV therapy for patients with localized scleroderma was introduced as PUVA in 1994 [42] . In 1995, Kerscher et al. [43] reported that low-dose UVA1 phototherapy could be used in linear scleroderma. It is unclear whether there is an association between initial skin disease duration and response to UVA1 therapy. A study of ten patients with sclerodermic lesions determined that there was no correlation between disease duration and clinical response with UVA1 [44] . improvement of their localized scleroderma as indicated by a clinical pinching test [56] .
Additionally, the ultrasound examination showed a dermal thickness reduction ranging from 20% to 100% [56] . There was no correlation between the type of phototherapy and clinical response rate [56] .
Additional studies on UVB therapies are included in Table 1 .
Targeted Phototherapy
Targeted phototherapy is a modality that spares non-lesional skin and is able to deliver a higher fluence. A patient with limited scleroderma and elbow mobility restrictions was treated 2-3 times a week for 13 weeks with 940-nm low-level light therapy with millisecond pulsing and continuous wave modes. Using a sequential pulsing dose on one elbow and continuous wave mode on the other, better results were seen with the pulsing mode showing improvement in skin thickness [57] .
Five patients with a total of 11 plaques were treated with a 308-nm monochromatic excimer laser for 4 weeks at a power density of 48 mW/ cm 2 with a maximum irradiation area of 512 cm 2 [58] . The mean number of treatments was seven, and the dose per session was 1.5 J/ cm 2 . The mean total dose was 10 J/cm 2 . After 4 weeks, 3 out of 5 patients experienced marked improvement with residual hyperpigmentation [58] .
A 27-year-old Hispanic female had a contracture of her knee with sclerotic bands on her left lower leg, ankle, and foot that were recalcitrant to methotrexate, UVA1, topical calcipotriene, intralesional triamcinolone acetonide, and physical therapy [59] . The patient was treated with a single treatment of 10.6 lm carbon dioxide laser with a 50 J/cm 2 pulse energy, while remaining on methotrexate and topical agents [59] . After 1 week, she experienced an increase in range of motion.
After 4 months of follow-up, there was softening of her contracture, and she regained full plantar flexion of her left foot. After a 1-year follow-up, she maintained a full range of motion [59] .
Four patients with microstomia and SSc were treated with intense pulsed light. 530-570 mm, 11-14 J/cm 2 ; 10-14 pulse durations was used for the patients every 4 weeks [60] . Patients were followed for 4 months. Three patients experienced an increased interincisal distance of *1 mm per treatment [60] . One patient did not have improved interincisal distance, but did note activities of daily living became easier. One patient did report recurrence of the stiffness after 3 weeks [60] . Table 1 lists additional reports of targeted phototherapy.
Photodynamic Therapy
In six patients, 20% 5-ALA was applied under occlusion to areas of morphea for 5 h. A band width of 570-670 nm, peak 635-nm light was given. A dose of 25 J/cm 2 was given for a total of six weekly treatments. In four of the patients there was clinical improvement as determined by skin scoring, although only one of these patients showed histologic evidence of improvement. The side effects patients reported included burning sensation, dryness, erythema, pigmentation, and pruritus [61] . Table 1 lists an additional study.
DISCUSSION
There are mostly care reports of UVA1, UVB, PUVA (bath and topical), and targeted phototherapies in cases of scleroderma. UVA1 appears to be the most efficacious, but it is also the most studied. There are not many studies on high-dose UVA1, and this needs to be investigated further to assess the optimal dose of UVA to use in scleroderma. Additionally, longer term studies are needed to study the long-term outcome and safety of these treatments. A similar literature review study delineated UVA and PUVA's efficacy and safety in the context of SSc, localized scleroderma, extragenital lichen sclerosus et atrophicus, sclerodermoid graft-versus-host disease, lupus erythematosus, and other rare sclerotic diseases [62] . This review also asserts that there need to be more rigorous studies to help establish a guide for UVA's indications as well as its efficacy compared to other conventional medical therapies [62] .
Based on the studies available, a reasonable regimen is UVA1 therapy 20-50 J/cm 2 3-4 times a week for a total of 30 treatments. There were no double-blind, placebo-controlled trials available, and only three controlled trials.
Adverse effects thus far do not correlate with the intensity of therapy. The side effects noted in scleroderma phototherapy include fatigue, a burning sensation, hyperpigmentation, pruritus, erythema, edema, headaches, gastrointestinal upset, and joint and muscle pain. Additionally, one patient undergoing UVA1 phototherapy for disseminated morphea developed bullous pemphigoid after 29 treatments [63] . The long-term effects of UVA1 on patients have not reported skin cancer [64] . Phototherapy should be safe in pregnancy [65] although folate may need to be supplemented 
